Therefore, the high EMT process in gemcitabine-resistant pancreatic cancer was confirmed to be regulated by the ZEB1-LOXL2 axis that contributes to maintaining chemoresistant characteristics. This evidence concerns the gene LOXL2 and familial pancreatic carcinoma.